/BTTX
BTTX Stock - Better Therapeutics, Inc.
Healthcare|BiotechnologyOTC
$0.00+0.00%
+$0.00 (+0.00%) • Dec 19
50
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.53
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BTTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.69
52W High$0.00
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Revenue | N/A | N/A | $8,000 | $18,000 |
| Gross Profit | $-2,729,000 | $-1,619,000 | $-674,000 | $-880,000 |
| Gross Margin | N/A | N/A | -8425.0% | -4888.9% |
| Operating Income | $-38,262,000 | $-30,560,000 | $-6,323,000 | $-5,773,000 |
| Net Income | $-39,760,000 | $-40,335,000 | $-6,387,000 | $-5,795,000 |
| Net Margin | N/A | N/A | -79837.5% | -32194.4% |
| EPS | $-1.69 | $-1.71 | $-1.04 | $-0.25 |
Company Overview
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BTTXBeat Rate
67%
Last 9 quarters
Avg Surprise
+8.0%
EPS vs Estimate
Beats / Misses
6/3
Last 12 quarters
Latest EPS
$-0.15
Q4 2023
EPS Surprise History
Q1 22
-54.3%
$-0.71vs$-0.46
Q2 22
-36.7%
$-0.41vs$-0.30
Q3 22
+10.6%
$-0.42vs$-0.47
Q4 22
+4.0%
$-0.48vs$-0.50
Q1 23
-39.2%
$-0.71vs$-0.51
Q1 23
+30.2%
$-0.37vs$-0.53
Q3 23
+38.5%
$-0.24vs$-0.39
Q4 23
+21.1%
$-0.15vs$-0.19
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Jun 4, 2025 | — | — | — | — |
Q2 2025 | May 29, 2025 | — | — | — | — |
Q1 2025 | Mar 28, 2025 | — | — | — | — |
Q4 2024 | Dec 27, 2024 | — | — | — | — |
Q3 2024 | Sep 25, 2024 | $-0.12 | — | — | — |
Q2 2024 | May 9, 2024 | $-0.12 | — | — | — |
Q1 2024 | Mar 12, 2024 | — | — | — | — |
Q4 2023 | Nov 9, 2023 | $-0.19 | $-0.15 | +21.1% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.39 | $-0.24 | +38.5% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-0.53 | $-0.37 | +30.2% | ✓ BEAT |
Q1 2023 | Mar 27, 2023 | $-0.51 | $-0.71 | -39.2% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.50 | $-0.48 | +4.0% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.47 | $-0.42 | +10.6% | ✓ BEAT |
Q2 2022 | May 13, 2022 | $-0.30 | $-0.41 | -36.7% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | $-0.46 | $-0.71 | -54.3% | ✗ MISS |
Q4 2021 | Nov 23, 2021 | $-1.66 | $-0.03 | +98.2% | ✓ BEAT |
Q3 2021 | Aug 20, 2021 | — | $-0.37 | — | — |
Q2 2021 | May 24, 2021 | — | $-0.23 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.09 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.50 | — | — |
Latest News
Loading news...
Frequently Asked Questions about BTTX
What is BTTX's current stock price?
Better Therapeutics, Inc. (BTTX) is currently trading at $0.00 per share. The stock has moved +0.00% today.
What is the analyst price target for BTTX?
No analyst price targets are currently available for this stock.
What sector is Better Therapeutics, Inc. in?
Better Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is BTTX's market cap?
Better Therapeutics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does BTTX pay dividends?
No, Better Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMPE
Ampio Pharmaceuticals, Inc.
$0.01
Mkt Cap: $0.0B
ARNI
Arno Therapeutics, Inc.
$0.00
Mkt Cap: $0.0B
BXRXQ
Baudax Bio, Inc.
$0.00
Mkt Cap: $0.0B
CALA
Calithera Biosciences, Inc.
$0.00
Mkt Cap: $0.0B
KLDO
Kaleido Biosciences, Inc.
$0.00
Mkt Cap: $0.0B
ONPH
Oncology Pharma Inc.
$0.01
Mkt Cap: $0.0B
PANC
Panacos Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
SCIE
SpectraScience, Inc.
$0.00
Mkt Cap: $0.0B
TLOG
TetraLogic Pharmaceuticals Corporation
$0.00
Mkt Cap: $0.0B
UPPR
Upper Street Marketing Inc.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to BTTX for comparison